Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENFLURANE vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Induction and maintenance of general anesthesia,Supplement to nitrous oxide and oxygen anesthesia
Management of mild to moderate pain,Reduction of fever
Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life is approximately 4-8 hours in adults; context: prolonged with obesity due to high lipid solubility and storage in adipose tissue.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Primarily hepatic via cytochrome P450 (CYP2E1); approximately 2% undergoes oxidative metabolism to difluoromethoxy-difluoroacetic acid and fluoride ions; rest is excreted unchanged by lungs.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily eliminated by pulmonary excretion as unchanged drug (>90%); less than 5% is metabolized via CYP2E1 to fluoride ions and other metabolites, which are renally excreted.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Approximately 55-75% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
10-25% bound to albumin at therapeutic concentrations.
Volume of distribution at steady state (Vdss) is approximately 3.5-4.5 L/kg, indicating extensive tissue distribution and lipid solubility.
0.8-1.0 L/kg; suggests distribution into total body water.
Inhalation: Bioavailability is essentially 100% as administered via inhalation, with rapid absorption across the alveolar-capillary barrier.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No specific GFR-based dose adjustment required; however, monitor for nephrotoxicity in severe renal impairment (e GFR <30 m L/min) due to potential fluoride ion accumulation.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce concentration; Child-Pugh C: avoid due to risk of hepatotoxicity and altered metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Induction: 1-4% inspired concentration; Maintenance: 0.5-2% inspired concentration; adjust based on age and response.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Reduce inspired concentration by 25-50% due to decreased minimal alveolar concentration (MAC) and increased sensitivity; monitor hemodynamics closely.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
None
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
May cause dose-dependent respiratory and cardiovascular depression,Risk of seizures (especially with deep anesthesia or hypocarbia),Potential for hepatotoxicity (rare, but caution in patients with pre-existing liver disease),Malignant hyperthermia risk,Should not be used in patients with known sensitivity to halogenated anesthetics
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Known hypersensitivity to enflurane or other halogenated anesthetics,Known or suspected genetic susceptibility to malignant hyperthermia,Severe hypotension or hypovolemia (relative),Prior history of hepatitis after halothane or other halogenated agents (relative)
Hypersensitivity to acetaminophen or any component of the formulation
No specific food interactions known for enflurane. Avoid alcohol for at least 24 hours post-anesthesia as it may increase sedation and hepatotoxicity risk.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Enflurane is not recommended during the first and second trimesters due to potential teratogenicity based on animal studies showing fetal malformations. During the third trimester, use is avoided for elective procedures as it may cause uterine relaxation and fetal depression. Risk is dose-dependent and duration-dependent.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Enflurane is excreted into breast milk in low concentrations. The M/P ratio is not well established but estimated around 0.5-1.0. Because of rapid clearance and minimal oral bioavailability, a single exposure is considered compatible with breastfeeding after waiting 24 hours. No adverse effects reported in infants.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
Pregnancy may decrease MAC (minimum alveolar concentration) by up to 40% due to progesterone and endogenous opioids. Dose should be reduced accordingly. No specific dose adjustment based on pharmacokinetic changes, but careful titration to effect is required.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Enflurane is a potent inhalation anesthetic that can cause dose-dependent myocardial depression and hypotension. It sensitizes the myocardium to catecholamines, increasing arrhythmia risk. Enflurane may provoke seizure activity at high concentrations or with hypocapnia. Malignant hyperthermia trigger. Use caution in patients with hepatic or renal impairment due to fluoride ion release.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
You will be unconscious and feel no pain during surgery.,You may experience nausea or shivering after waking up.,Inform your anesthesiologist if you have a personal or family history of malignant hyperthermia.,Avoid operating machinery or driving for at least 24 hours after anesthesia.,Report any unusual muscle stiffness, fever, or dark urine after surgery.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
"Enflurane, a halogenated volatile anesthetic, and venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), both inhibit neuronal reuptake of monoamines, leading to increased central nervous system (CNS) levels of serotonin and norepinephrine. Concurrent use may potentiate the risk of serotonin syndrome, characterized by agitation, hyperthermia, autonomic instability, and neuromuscular hyperactivity. Additionally, venlafaxine can lower the seizure threshold, while enflurane may produce epileptiform EEG activity, raising the potential for perioperative seizures."
"Enflurane is a halogenated volatile anesthetic that potentiates the effects of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to central nervous system (CNS) depression. Tiapride, a selective dopamine D2 receptor antagonist, can also cause CNS depression and prolong the QT interval. Combined use may result in additive CNS depression, increasing the risk of excessive sedation, respiratory depression, and hypotension. Additionally, both drugs can lower the seizure threshold, potentially increasing the risk of perioperative seizures."
"The combination of enflurane and levobupivacaine increases the risk of cardiotoxicity and central nervous system (CNS) toxicity. Enflurane sensitizes the myocardium to the arrhythmogenic effects of levobupivacaine, potentially leading to severe ventricular arrhythmias. Additionally, both drugs depress myocardial contractility and conduction, which may result in hypotension, bradycardia, or cardiac arrest."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENFLURANE vs INJECTAPAP, answered by our medical review team.
ENFLURANE is a Inhalational Anesthetic that works by Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENFLURANE and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENFLURANE is: Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENFLURANE and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENFLURANE is classified as Category C. Enflurane is not recommended during the first and second trimesters due to potential teratogenicity based on animal studies showing fetal malformations. During the third trimester,. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.